Skip to Content

I-MAB ADR IMAB Stock Quote

| Rating as of

Morningstar‘s Stock Analysis IMAB

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


I-Mab's Interim Results Hold No Surprises; Still a Long Road to Approval of Global Assets

Jay Lee Senior Equity Analyst

Analyst Note

| Jay Lee |

I-Mab’s interim results update held few surprises and confirmed our view of the company’s near-term prospects. We no longer think I-Mab is a front-runner in the CD47 race in the lucrative U.S. market, although it remains a leader in the much smaller Chinese market. Its near-term commercial prospects now depend on felzartamab (CD38 inhibitor for multiple myeloma) and eftansomatropin (long-acting growth hormone) in the domestic China market.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics IMAB

Company Profile IMAB

Business Description

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.

555 West Haiyang Road, 55th - 56th Floor, New Bund Center
Shanghai, 200124, China, People's Republic of
T +86 2160578000
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2022
Employees 378

Related News IMAB